CN116322766A - 抗cd2抗体 - Google Patents

抗cd2抗体 Download PDF

Info

Publication number
CN116322766A
CN116322766A CN202180056349.5A CN202180056349A CN116322766A CN 116322766 A CN116322766 A CN 116322766A CN 202180056349 A CN202180056349 A CN 202180056349A CN 116322766 A CN116322766 A CN 116322766A
Authority
CN
China
Prior art keywords
antibody
subject
dose
binding fragment
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180056349.5A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·伯格朗德
埃里克·伯格朗德
菲利克斯·塞尔伯格
克里斯蒂安·宾德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zelarion Malta Ltd
Original Assignee
Zelarion Malta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zelarion Malta Ltd filed Critical Zelarion Malta Ltd
Publication of CN116322766A publication Critical patent/CN116322766A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180056349.5A 2020-06-23 2021-06-22 抗cd2抗体 Pending CN116322766A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063042844P 2020-06-23 2020-06-23
US63/042,844 2020-06-23
US202163135381P 2021-01-08 2021-01-08
US63/135,381 2021-01-08
US202163182095P 2021-04-30 2021-04-30
US63/182,095 2021-04-30
PCT/EP2021/066989 WO2021259927A2 (en) 2020-06-23 2021-06-22 Anti-cd2 antibodies

Publications (1)

Publication Number Publication Date
CN116322766A true CN116322766A (zh) 2023-06-23

Family

ID=76730545

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180056349.5A Pending CN116322766A (zh) 2020-06-23 2021-06-22 抗cd2抗体

Country Status (9)

Country Link
US (2) US20230365687A1 (https=)
EP (1) EP4168035A2 (https=)
JP (2) JP2023531251A (https=)
CN (1) CN116322766A (https=)
AU (1) AU2021298111A1 (https=)
BR (1) BR112022026429A2 (https=)
CA (1) CA3188130A1 (https=)
MX (1) MX2022016039A (https=)
WO (1) WO2021259927A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023224980A1 (en) * 2022-05-17 2023-11-23 The Uab Research Foundation Methods and compositions for treating or preventing inflammatory skin disorders
US20240228620A1 (en) 2022-10-06 2024-07-11 Bicara Therapeutics Inc. Multispecific proteins and related methods
WO2024079046A1 (en) * 2022-10-10 2024-04-18 Zelarion Malta Limited Anti-cd2 antibodies for type 1 diabetes
EP4673468A1 (en) 2023-03-01 2026-01-07 Zelarion Malta Limited Anti-cd2 antibodies for amyotrophic lateral sclerosis
KR20260016903A (ko) * 2023-05-30 2026-02-04 임노테크 쥐엠비에이치 항-cd2 단일 도메인 항체, 암 진단 및/또는 치료용 약학적 조성물 및 키트
WO2025207763A1 (en) * 2024-03-27 2025-10-02 Zelarion Malta Limited Method and composition for inducing tolerance of transplanted organ or tissue
WO2026052700A1 (en) 2024-09-05 2026-03-12 Zelarion Malta Limited Anti-cd2 antibodies for amyotrophic lateral sclerosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2327980T3 (es) * 1996-08-16 2009-11-05 Biotransplant, Inc Anticuerpo lo- d2a y sus usos para inhibir la activacion y la proli feracion de celulas t.
US6692743B1 (en) * 1998-05-08 2004-02-17 Universite Catholique De Louvain Apoptosis of naive human NK cells by crosslinking of their FcγRIIIa molecules with a rat IgG2b (LO-CD2a/BTI-322) or its IgG1 humanized monoclonal antibody
AU2002250236A1 (en) * 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
WO2004022097A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
JP2013540731A (ja) * 2010-09-08 2013-11-07 イェダ リサーチ アンド デベロップメント カンパニー リミテッド 安定かつ長期間の生着のための免疫抑制薬物組合せ
BR112020010816A2 (pt) * 2017-11-29 2020-11-10 Magenta Therapeutics, Inc. composições e métodos para a depleção de células de cd2+

Also Published As

Publication number Publication date
MX2022016039A (es) 2023-05-04
WO2021259927A3 (en) 2022-03-17
BR112022026429A2 (pt) 2023-04-18
JP2026053445A (ja) 2026-03-25
WO2021259927A2 (en) 2021-12-30
US20240270845A1 (en) 2024-08-15
AU2021298111A1 (en) 2023-02-09
US20230365687A1 (en) 2023-11-16
JP2023531251A (ja) 2023-07-21
CA3188130A1 (en) 2021-12-30
EP4168035A2 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
CN116322766A (zh) 抗cd2抗体
US20250026850A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
US11466087B2 (en) Anti-CLL-1 antibodies and methods of use
EP3606954B1 (en) Anti-lag3 antibodies
AU2022231722A1 (en) Humanized and affinity matured antibodies to FcRH5 and methods of use
CN106573050B (zh) 特异性结合多种癌症抗原的三特异性结合分子和其使用方法
JP7624493B2 (ja) 抗ｃｔｌａ－４抗体およびその使用
CN115551894A (zh) 新型抗lilrb4抗体和衍生产物
CN110023338A (zh) 用于与抗pd-l1抗体组合的抗tim-3抗体
RS66218B1 (sr) Anti-cd154 antitela i njihove upotrebe
KR20240024318A (ko) T 세포 활성화 이중특이적 항원 결합 분자 CD3 ABD 엽산 수용체 1(FolR1) 및 PD-1 축 결합 길항물질의 조합 요법
WO2022270611A1 (ja) 抗ｃｔｌａ－４抗体
CN108779178A (zh) 抗mica抗体
KR20180089510A (ko) CD32b를 표적화하는 항체 및 그의 사용 방법
CN116789820A (zh) 一种新型免疫调节剂的开发和应用
WO2023126445A1 (en) Anti-cd2 antibodies
HK40102691A (zh) 用经修饰的抗-cd154抗体诱导免疫耐受的方法
HK40086532A (zh) 新型抗lilrb4抗体和衍生产物
EA045931B1 (ru) Анти-ctla-4 антитело и его применение
HK40083599B (zh) 抗-ctla-4抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination